ML-TRIZ-5 / RM-MET
Tirzepatide
A dual GIP/GLP-1 receptor agonist peptide. The active ingredient appears in an FDA-approved product, which establishes that the molecule is well characterised — it says nothing about any individual third-party vial.
The listed price is the four-week total for this weekly option. Eight- and twelve-week totals are calculated as exact two- and three-month multiples.
Evidence position
Approved comparator existsEvidence grade A: Approved comparator exists
Grade A. An FDA-approved comparator containing this active exists. The approved product's identity, strength, sterility and controls do not transfer to material sourced elsewhere.
Comparator: Zepbound (tirzepatide) — FDA approved. Not this material.
Full reference entryDocuments
- Lot
- Assigned at fulfilment
- Origin
- Confirmed with the lot record
- Analytical record
- Lot-linked documentation is confirmed with the written response.
Monthly supply options
- ○ML-TRIZ-2.52.5 mg weekly4-week priceVerifyingSupplyVerifying
- ●ML-TRIZ-55 mg weekly4-week priceVerifyingSupplyVerifying
- ○ML-TRIZ-7.57.5 mg weekly4-week priceVerifyingSupplyVerifying
- ○ML-TRIZ-1010 mg weekly4-week priceVerifyingSupplyVerifying
- ○ML-TRIZ-12.512.5 mg weekly4-week priceVerifyingSupplyVerifying
- ○ML-TRIZ-1515 mg weekly4-week priceVerifyingSupplyVerifying